Longeveron Management
Management criteria checks 0/4
Longeveron's CEO is Steve Willard, appointed in Feb 2026, has a tenure of less than a year. directly owns 2.44% of the company’s shares, worth $591.11K. The average tenure of the management team and the board of directors is 1.7 years and 1.5 years respectively.
Key information
Steve Willard
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 2.4% |
| Management average tenure | 1.7yrs |
| Board average tenure | 1.5yrs |
Recent management updates
Recent updates
Narrative Update • Jul 10
LGVN: Trial Safety Progress And EMA SME Status Will Support Future Repricing
Analysts have revised their Longeveron fair value estimate to a range of $2.00 to $3.00 per share, reflecting updated assumptions around revenue growth, profit margins, and a higher future P/E multiple, while also accounting for a more cautious stance highlighted by Maxim's recent downgrade. What’s in the News for Longeveron Longeveron received Small or Medium-sized Enterprise status from the European Medicines Agency, giving the company access to scientific advice, regulatory guidance, and reduced administrative fees during drug development, according to the EMA SME program description.
Narrative Update • Jun 26
LGVN: Upcoming HLHS Trial Outcome Will Drive Upside Potential
Analysts have raised their price target on Longeveron from $5.82 to $7.15, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E, even as some recent Street research has become more cautious on the stock. What’s in the News for Longeveron Longeveron received Small or Medium sized Enterprise status from the European Medicines Agency, giving the company access to scientific advice, regulatory guidance, and reduced administrative fees during clinical development in Europe.Narrative Update • Apr 23
LGVN: Nasdaq Compliance Extension And Trial Progress Will Support Future Repricing
Analysts have trimmed their price target on Longeveron by $1 to reflect slightly different assumptions on the discount rate, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Bearish analysts recently trimmed their Longeveron price target by US$1, citing changes in assumptions for discount rates, revenue growth, profit margins, and future P/E expectations.Narrative Update • Apr 09
LGVN: Nasdaq Compliance Extension And Clinical Progress Will Support Future Repricing
Analysts have lowered their price target on Longeveron by $1, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Bearish analysts cutting the price target by $1 are signaling a more cautious stance on what they see as Longeveron’s risk and reward tradeoff.Narrative Update • Mar 26
LGVN: ELPIS II Pivotal Trial And Nasdaq Extension Will Drive Future Repricing
Analysts trimmed their price target on Longeveron by $1, citing updated assumptions that now reflect a fair value of 2.0, a discount rate of 7.08457895304031, revenue growth of 37.91869977802995, a profit margin of 14.774604420000001, and a future P/E of 147.96681297821388. Analyst Commentary Bearish analysts trimming the price target by $1 are signaling that, in their view, the updated assumptions justify a more conservative stance on Longeveron.Narrative Update • Mar 12
LGVN: Upcoming HLHS Trial Meeting Will Drive Upside Potential
Analysts trimmed their price target on Longeveron to $5.82, reflecting updated assumptions that include a slightly lower discount rate, revised profit margin expectations, and a higher projected P/E multiple in their models. What's in the News Longeveron entered a definitive agreement for a private placement with Coastlands Capital, Janus Henderson Investors, Logos Capital and Kalehua Capital, targeting gross proceeds of US$30 million through Class A common stock and Series A Non Voting Convertible Preferred Stock.Narrative Update • Feb 26
LGVN: Upcoming HLHS Meeting And Trial Pathway Will Drive Upside Potential
Analysts have adjusted their price target for Longeveron, maintaining it at $5.82, as they revisit assumptions around future revenue growth, profit margins, discount rate, and expected P/E. These revisions reflect a more balanced view of the company's long term potential and risk profile.Narrative Update • Feb 11
LGVN: Upcoming HLHS Trial Readout Will Drive Future Upside Potential
Analysts have lowered their price target on Longeveron from about $6.86 to roughly $5.82. They now factor in a higher discount rate, stronger revenue growth expectations, a lower profit margin outlook, and a slightly higher future P/E multiple.Narrative Update • Aug 15
FDA Alignment And HLHS Trial Will Enable Market Access
Longeveron's valuation outlook has strengthened, with a sharp drop in its forward P/E multiple and improved net profit margin indicating better profitability and a more attractive risk-reward profile, though the consensus analyst price target remains unchanged at $8.39. What's in the News Longeveron completed a $17.5 million follow-on equity offering, issuing 5.62 million shares of Class A common stock, 14.71 million warrants, and 265,000 pre-funded warrants at $0.85 per security.Analysis Article • Jul 10
Can Longeveron (NASDAQ:LGVN) Afford To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although...
New Narrative • Apr 15
ELPIS II And Alzheimer Programs Will Accelerate FDA Approval
Successful trial enrollment and regulatory designations could accelerate Longeveron's market entry and future revenue growth through streamlined FDA pathways and partnerships.Analysis Article • Mar 05
Is Longeveron (NASDAQ:LGVN) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...CEO
Steve Willard (65 yo)
less than a year
Tenure
Mr. Stephen H. Willard, also known as Steve, Esq., is Chief Executive Officer at Longeveron Inc. since February 11, 2026 and serves as its Director from July 01, 2026. He was Acting Corporate Secretary at...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 12.6yrs | US$523.01k | 2.28% $ 552.9k | |
| General Counsel & Secretary | no data | US$1.05m | 1.82% $ 440.8k | |
| CEO & Director | less than a year | no data | 2.44% $ 591.1k | |
| Senior VP | less than a year | no data | no data | |
| CTO and Senior VP of Chemistry | 1.7yrs | no data | 1.35% $ 326.1k | |
| Chief Medical Officer | 3.1yrs | no data | 1.36% $ 330.1k | |
| Vice President of Manufacturing | no data | no data | no data | |
| Vice President of Research & Discovery | no data | no data | no data |
1.7yrs
Average Tenure
56yo
Average Age
Experienced Management: LGVN's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 12.6yrs | US$523.01k | 2.28% $ 552.9k | |
| CEO & Director | less than a year | no data | 2.44% $ 591.1k | |
| Independent Director | 2.1yrs | US$87.81k | 0.017% $ 4.1k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | 6.4yrs | US$69.99k | 0.85% $ 204.6k | |
| Independent Director | 5.2yrs | US$88.69k | 0.13% $ 31.4k | |
| Independent Director | less than a year | US$44.33k | no data |
1.5yrs
Average Tenure
62yo
Average Age
Experienced Board: LGVN's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/10 07:43 |
| End of Day Share Price | 2026/08/07 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Longeveron Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |
| Michael Okunewitch | Maxim Group |